Vered Bisker-Leib is the Chief Operating Officer of Compass Therapeutics. In this role, she leads a team that spearhead finance, corporate development, strategy, operations, and public and investor relations. Prior to Compass, Vered served as an entrepreneur-in-residence with Atlas Venture, where she provided business guidance to seed-stage companies. Previously, she was the chief business officer of Cydan, a biotech accelerator, where she co-founded biotech companies focused on therapies addressing rare diseases. Before joining Cydan, Vered was a member of Bristol-Myers Squibb’s strategic transactions group where she assumed roles of increasing responsibility across five therapeutic areas, most recently as an executive director and global head of business development for the cardiovascular and metabolic franchises. At Bristol-Myers Squibb, Vered led a team responsible for creating and executing business development strategy and facilitated the licensing of pre-clinical and clinical stage programs from Alder BioPharmaceuticals, Ambrx and Portola Pharmaceuticals, as well as the acquisitions of ZymoGenetics, Amira Pharmaceuticals and Amylin Pharmaceuticals, among others. Earlier in her career, Vered held business development roles at Avalon Pharmaceuticals and MedImmune after beginning her career as a scientist at Baxter.
Vered concurrently earned her PhD in chemical engineering and MBA from University of Massachusetts, Amherst, where she was a Lois Pope MBA Scholar. She has a BSc in chemical engineering from the Israel Institute of Technology in Haifa.